US pharmaceutical company AbbVie (NYSE: ABBV) announced on Thursday that it has entered into a new discovery, co-development and licence agreement with Gedeon Richter plc, a pharmaceutical and biotechnology company based in Hungary.
This collaboration aims to advance novel targets for the potential treatment of neuropsychiatric conditions.
AbbVie said that the partnership builds on the success of around two decades of collaboration on central nervous system (CNS) projects, including globally launched products such as cariprazine (VRAYLAR / REAGILA) and the discovery of investigational drug candidate ABBV-932 for the treatment of bipolar depression and generalised anxiety disorder.
Under the terms of the agreement, the partnership includes both preclinical and clinical R&D activities with financing shared by the companies. Richter will receive an upfront cash payment of USD25m, along with potential future development, regulatory and commercialisation milestones. Richter may also receive sales-based royalties. AbbVie will have global commercialisation rights except for Richter's traditional markets, such as geographic Europe, Russia, other CIS countries and Vietnam.
PTC Therapeutics submits vatiquinone NDA to US FDA
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
IXICO signs commercial agreement with PETNET Solutions to enhance neuroimaging capabilities
Newron and EA Pharma sign licensing deal for Evenamide in Asia
GC Biopharma and Novel Pharma report first patient dosed in multinational trial of GC1130A
Merck's WELIREG approved in China for VHL disease
AbbVie signs new discovery, co-development and licence agreement with Gedeon Richter
JCR Pharmaceuticals showcases preclinical gene therapy advances at ESGCT Congress
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Charles River and Lundbeck partner to advance neurological drug discovery using AI-powered Logica
Vesper Bio announces positive Phase I results for FTD treatment
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Argent BioPharma partners with SINTEF to advance chronic wound management